Relaxin-3–RXFP3 signaling: a laboratory assay research guide

1) Treat relaxin-3 as a folded molecular reagent

Relaxin-3, historically called H3 relaxin, belongs to the insulin/relaxin peptide family. Its mature form contains separate A and B chains connected by two interchain disulfides, with a third disulfide within the A chain. This topology matters experimentally: correct intact mass does not by itself establish the native disulfide connectivity, and a reduced, scrambled, or partially oxidized preparation can have a very different pharmacological profile.

Bathgate and colleagues used stepwise, regioselective disulfide formation to synthesize human relaxin-3 and demonstrated activity at GPCR135, now RXFP3, while also documenting activity at other relaxin-family receptors.^[1] A test article should therefore state the A- and B-chain sequences, terminal chemistry, disulfide map, counterion, analytical purity, absolute peptide content, and lot. Verify intact mass by LC-MS and resolve major oxidized species by HPLC. When connectivity is central to the question, use disulfide mapping rather than inferring correct folding from one chromatographic peak.

Measure recovery after dilution into the real assay medium and plate type. Two-chain peptides may adsorb to plastic or undergo reduction, exchange, aggregation, or proteolysis. Analyze a time-zero sample and a sample held for the longest exposure interval. Molarity should be based on peptide content rather than gross lyophilized mass, which may include counterions and water.

2) Prove that RXFP3 causes the measured response

RXFP3 has appeared as GPCR135 and SALPR in older literature. Record species, accession, full construct sequence, tag location, host cell, and passage range. Compare receptor-expressing cells with parental or engineered receptor-null cells, then restore the response with sequence-verified rescue. In native preparations, combine expression evidence with an orthogonal perturbation such as knockdown, knockout, or a pharmacologically characterized antagonist.

Surface abundance is a critical covariate. Quantify it by surface ELISA, flow cytometry, or another calibrated method rather than relying on transfected DNA or total fluorescent signal. Match receptor abundance when comparing mutants, ligands, or cell backgrounds. High receptor reserve can shift apparent potency and hide partial agonism, while low surface delivery can mimic weak coupling.

Relaxin-3 can activate receptors outside RXFP3 under some assay conditions, and other relaxin-family peptides can produce signals in RXFP3-expressing systems.^[1][3] Include counterscreens against RXFP1, RXFP2, and RXFP4 when claiming selectivity. A response lost in an RXFP3-null cell is stronger evidence than antagonist sensitivity alone because antagonists can have incomplete selectivity or context-dependent efficacy.

3) Design the Gi/o–cAMP experiment around a stimulated baseline

RXFP3 is commonly characterized as a Gi/o-coupled receptor that inhibits adenylyl cyclase. Because basal cAMP may be close to the lower limit of a reporter, establish a reproducible stimulated baseline with forskolin or another validated activator, then measure the concentration-dependent decrease after relaxin-3. Report the stimulant concentration, preincubation, exposure time, phosphodiesterase inhibitor if any, sensor range, baseline, and normalization method.

Pertussis toxin sensitivity can support Gi/o involvement, but it is not sufficient alone. Confirm that treatment blocks a known Gi/o control and does not compromise cell number, viability, or the cAMP sensor. Pair the accumulated cAMP endpoint with a proximal method such as mini-Gi recruitment, nucleotide exchange, or a validated BRET biosensor. Proximal kinetics can distinguish receptor coupling from changes arising later through phosphodiesterases or feedback.

Use full concentration–response curves with independent biological replicates. Report maximal inhibition and confidence intervals alongside potency. Apparent EC50 depends on receptor reserve, stimulant level, assay duration, and reporter amplification, so values from different platforms should not be treated as fixed molecular constants. Randomize plate position and include vehicle, receptor-null, receptor-independent high-cAMP, and low-cAMP controls on every plate.

4) Resolve ERK1/2 as a timed, context-dependent output

Van der Westhuizen and colleagues found that RXFP3 activation by H3 relaxin stimulated ERK1/2 in CHO, HEK293, and SN56 neuronal cells. The response required Gi/o and was predominantly protein-kinase-C dependent, with contributions from PI3K and Src; details differed by host cell, and receptor internalization or lipid-rich compartmentalization appeared important.^[2] ERK is therefore useful as an orthogonal signal, but it cannot be interpreted as a direct proxy for Gi/o engagement.

Collect a time course before selecting a comparison point. Quantify phosphorylated and total ERK in the same samples, preserve rapid kinetics during lysis, and include a receptor-independent ERK control. Test pathway inhibitors only at concentrations shown not to disrupt baseline viability or assay chemistry. If endocytosis is implicated, pair pharmacological perturbation with imaging or surface-loss measurements; a trafficking inhibitor can alter many cellular processes besides receptor movement.

Transcriptional reporters integrate signaling over hours and can reverse ligand rankings seen at proximal endpoints. In RXFP3-expressing cells, H3 relaxin strongly inhibited stimulated cAMP and activated ERK and NF-κB, whereas H2 relaxin showed relatively stronger AP-1 reporter activity in the experimental systems used by van der Westhuizen and colleagues.^[3] Such results motivate pathway-bias experiments, but bias should be estimated from matched full curves and a reference ligand, not from isolated percentages at one concentration.

5) Separate binding, activation, and peptide-engineering questions

Mutagenesis studies place important relaxin-3 contacts in the B chain and acidic residues in RXFP3 extracellular regions. Bathgate and colleagues used comparative modeling and receptor mutagenesis to investigate electrostatic contacts involving critical B-chain arginines.^[4] Binding and activation remain distinct: a mutation may reduce surface expression, disrupt affinity, or uncouple efficacy. Each receptor mutant needs surface quantification, ligand binding, and at least one proximal functional assay.

Simplified single-chain tools are not interchangeable with native relaxin-3. Haugaard-Kedström and colleagues synthesized and characterized more than 60 analogues of the linear antagonist R3 B1-22R. Their data identified the nonnative C-terminal Arg as a major affinity determinant and supported a helical receptor-bound conformation, while helix-breaking substitutions disrupted binding.^[5] These findings are valuable for control design, but they also show why an analogue must be named and chemically verified rather than described generically as “relaxin-3.”

For ligand comparisons, determine binding affinity and functional potency in the same receptor background. Include native relaxin-3 as the reference on every experiment day. A low functional maximum can reflect partial agonism, degradation, poor recovery, slow equilibration, or inadequate receptor reserve. Orthogonal chemical recovery and binding measurements separate these explanations.

6) Translate from recombinant cells into neuronal preparations

Recombinant cells provide receptor-defined null controls and quantitative curve fitting; neurons supply native channels and signaling architecture. Kania and colleagues combined rat hypothalamic slices, electrophysiology, receptor pharmacology, and expression mapping. Relaxin-3 or the selective agonist RXFP3-A2 hyperpolarized many magnocellular paraventricular neurons, persisted during blockade of action potentials and fast synaptic transmission, and was prevented by intracellular pertussis toxin; a cadmium-sensitive outward current was implicated.^[6]

That design illustrates how to move beyond correlation. In slice work, report species, sex, age, region, cutting and recovery conditions, artificial cerebrospinal fluid, temperature, holding conditions, access-resistance rules, application kinetics, and cell-identification method. Demonstrate that a response is postsynaptic where claimed, confirm RXFP3 expression in the recorded cell class, and include an antagonist or genetic control.

Do not assume a cAMP result predicts membrane excitability. Gi/o can affect ion channels through subunits and intermediate pathways, while ERK and transcription integrate over different time scales. A strong validation program links receptor-defined cell assays to one mechanistically explicit neuronal endpoint without treating either model as a complete representation of an organism.

7) A reproducible relaxin-3–RXFP3 workflow

1. Define the reagent. Record both chains, termini, disulfides, counterion, purity, peptide content, lot, and modifications.
2. Verify exposure. Measure intact recovery in the actual medium, vessel, concentration range, and incubation window.
3. Specify the receptor. Report species, accession, complete sequence, tag, host, passage, and surface abundance.
4. Prove causality. Combine null cells, knockout or knockdown, rescue, and receptor-competence controls.
5. Resolve pathways. Measure proximal Gi/o, stimulated cAMP, and timed ERK rather than relying on one distal reporter.
6. Test selectivity. Counterscreen relaxin-family receptors and use native relaxin-3 as the same-day reference.
7. Predefine analysis. State curve model, biological replicate hierarchy, exclusion rules, and uncertainty reporting.

A rigorous relaxin-3 experiment connects a chemically and conformationally verified peptide to quantified surface RXFP3, demonstrates receptor dependence, resolves Gi/o-cAMP and ERK kinetics, and tests family-level selectivity. Those controls turn a signal change into an interpretable receptor mechanism.